# EDGAR Filing Document

**Accession Number:** 0001869333
**File Stem:** 0001123292-25-000387
**Filing Date:** 2025-8
**Character Count:** 15763
**Document Hash:** a275f49c6e176d7255bd6228673e8715
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001123292-25-000387.hdr.sgml**: 20250826

**ACCESSION NUMBER**: 0001123292-25-000387

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250826

**DATE AS OF CHANGE**: 20250826

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Stoke Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001623526
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 471144582
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91051
- **FILM NUMBER:** 251258919

**BUSINESS ADDRESS:**
- **STREET 1:** 45 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730
- **BUSINESS PHONE:** 781-430-8200

**MAIL ADDRESS:**
- **STREET 1:** 45 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASOthera Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20141028
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Skorpios Trust
- **CENTRAL INDEX KEY:** 0001869333

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** G4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 195 ARCH. MAKARIOS III AVE.
- **STREET 2:** NEOCLEOUS HOUSE
- **CITY:** LIMASSOL
- **STATE:** G4
- **ZIP:** 3030
- **BUSINESS PHONE:** 3-572-511-0165

**MAIL ADDRESS:**
- **STREET 1:** 195 ARCH. MAKARIOS III AVE.
- **STREET 2:** NEOCLEOUS HOUSE
- **CITY:** LIMASSOL
- **STATE:** G4
- **ZIP:** 3030

## Ex-1

#### Exhibit 1

#### Joint Filing Agreement
The undersigned hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Date: August 26, 2025

---

| | |
|:---|:---|
| **Blue Horizon Enterprise Ltd.** | **Blue Horizon Enterprise Ltd.** |
| By: | /s/ Eleni Constantinou Kyriacou |
| Name: | Eleni Constantinou Kyriacou |
| Title: | Director |
| **Ezbon International Limited** | **Ezbon International Limited** |
| By: | /s/ Eleni Constantinou Kyriacou |
| Name: | Eleni Constantinou Kyriacou |
| Title: | Director |

---

---

| | |
|:---|:---|
| **Montrago Trustees Limited** | **Montrago Trustees Limited** |
| By: | /s/ Androulla Papadopoulou |
| Name: | Androulla Papadopoulou |
| Title: | Director |

---

---

| | |
|:---|:---|
| **Skorpios Trust** | **Skorpios Trust** |
| By: | /s/ Androulla Papadopoulou |
| Name: | Androulla Papadopoulou |
| Title: | Director |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 6)**

**Stoke Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**86150R107**

*(CUSIP Number)*

**Patrik Blochlinger, Chief Lega**<br>Rigmora (Switzerland) Ltd<br>Stockerstrasse 8<br>Zurich V8 8002<br>41 44 287 2498

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/22/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **86150R107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Blue Horizon Enterprise Ltd** | Name of reporting person<br>**Blue Horizon Enterprise Ltd** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1967621.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1967621.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1967621.00** | Aggregate amount beneficially owned by each reporting person<br>**1967621.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.6%** | Percent of class represented by amount in Row (11)<br>**3.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** The percentages used herein and in the rest of this Schedule 13D are calculated based upon 54,797,418 shares of the Issuer's common stock outstanding as of July 31, 2025, as reported in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2025.

| **CUSIP No.** | **86150R107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ezbon International Ltd** | Name of reporting person<br>**Ezbon International Ltd** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**288560.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**288560.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**288560.00** | Aggregate amount beneficially owned by each reporting person<br>**288560.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.5%** | Percent of class represented by amount in Row (11)<br>**0.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **86150R107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Montrago Trustees Ltd** | Name of reporting person<br>**Montrago Trustees Ltd** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**G4** | Citizenship or place of organization<br>**G4** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2256181.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2256181.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2256181.00** | Aggregate amount beneficially owned by each reporting person<br>**2256181.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.1%** | Percent of class represented by amount in Row (11)<br>**4.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **86150R107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Skorpios Trust** | Name of reporting person<br>**Skorpios Trust** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**G4** | Citizenship or place of organization<br>**G4** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2256181.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2256181.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2256181.00** | Aggregate amount beneficially owned by each reporting person<br>**2256181.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.1%** | Percent of class represented by amount in Row (11)<br>**4.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
Stoke Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
45 Wiggins Ave., Bedford, MA, 01730

This Amendment No. 6 (the "Amendment No. 6") is filed by Skorpios Trust, Montrago Trustees Limited ("Montrago Trustees"), Ezbon International Limited ("Ezbon") and Blue Horizon Enterprise Ltd. ("Blue Horizon" and, collectively, the "Reporting Persons") and amends the Schedule 13D filed by the Reporting Persons on June 30, 2021, as amended by Amendment No. 1 to Schedule 13D filed by the Reporting Persons on April 18, 2024, Amendment No. 2 to Schedule 13D filed by the Reporting Persons on September 23, 2024, Amendment No. 3 to Schedule 13D filed by the Reporting Persons on December 27, 2024, Amendment No. 4 to Schedule 13D filed by the Reporting Persons on June 6, 2025 and Amendment No. 5 to Schedule 13D filed by the Reporting Persons on June 23, 2025 (as amended, the "Schedule 13D"). The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 6 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the Schedule 13D.

**Item 4. Purpose of Transaction**

Item 4 is hereby amended and supplemented by adding the following:

On August 22, 2025, Blue Horizon sold 1,000,000 Shares of the Issuer in an open market transaction at a price of $18.50 per share.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) is hereby amended and restated as follows: (a) The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference.

**(b)**
Item 5(b) is hereby amended and restated as follows: (b) The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference.

**(c)**
Item 5(c) is hereby amended and restated as follows: (c) The information reported in Item 4 is incorporated herein by reference. Other than as disclosed in that item, no transactions in the Shares have been effected by the Reporting Person during the past sixty (60) days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Blue Horizon Enterprise Ltd

**Signature:** /s/ Eleni Constantinou Kyriacou

**Name/Title:** Eleni Constantinou Kyriacou, Director

**Date:** 08/26/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ezbon International Ltd

**Signature:** /s/ Eleni Constantinou Kyriacou

**Name/Title:** Eleni Constantinou Kyriacou, Director

**Date:** 08/26/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Montrago Trustees Ltd

**Signature:** /s/ Androulla Papadopoulou

**Name/Title:** Androulla Papadopoulou, Director

**Date:** 08/26/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Skorpios Trust

**Signature:** /s/ Androulla Papadopoulou

**Name/Title:** Androulla Papadopoulou, Director

**Date:** 08/26/2025